Small molecule high throughput screen using AstraZeneca facilities

This collaboration agreement, issued by the Medical Research Council under UK Research and Innovation, facilitates a small molecule high throughput screen utilizing AstraZeneca facilities. The project focuses on identifying compounds with activity against a specific target, with AstraZeneca providing a Hit Nomination Document specifying the chemical structures of up to 15 hit candidates to enable further project progression. The agreement is governed by English law and requires the participating institution to manage the project through a designated Principal Investigator and key personnel. Financial administration involves the institution invoicing the MRC for remuneration based on a research budget, with payments due within 60 days of receipt. AstraZeneca will separately invoice the institution for reimbursement of project costs. Strict compliance standards are mandated, including adherence to the UK Human Tissue Act 2004 for biological samples and the AstraZeneca International Policy on Animal Care and Use. Animal research must follow global standards and European Convention principles, with AstraZeneca conducting direct inspections of any facilities involving primate studies. Additionally, the agreement prohibits the unauthorized characterization or structural determination of compounds from the AZ Compound Collection, which is classified as confidential information.